Merck & Company, Inc. with ticker code (MRK) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The range between the high target price and low target price is between 135 and 96 and has a mean target at $119.54. Now with the previous closing price of $104.80 and the analysts are correct then there would likely be a percentage uptick in value of 14.1%. The day 50 moving average is $107.51 and the 200 day moving average is $98.78. The market cap for the company is $271,451m. Company Website: https://www.merck.com
The potential market cap would be $309,631m based on the market consensus.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
The company has a dividend yield of 2.73% with the ex dividend date set at 14-3-2023 (DMY).
Other points of data to note are a P/E ratio of 18.73, revenue per share of 23.41 and a 11.96% return on assets.
